paritaprevir + ritonavir + ombitasvir + peginterferon alfa-2a + ribavirin

This drug is a five-component combination regimen consisting of **paritaprevir**, **ritonavir**, **ombitasvir**, **peginterferon alfa-2a**, and **ribavirin**. It is used for the treatment of chronic hepatitis C virus (HCV) infection, particularly in patients with genotype 1 or 4, though differences in regimen components exist by genotype and country. Paritaprevir is an HCV NS3/4A protease inhibitor; ritonavir is a CYP3A inhibitor used here as a pharmacokinetic enhancer to boost paritaprevir levels; ombitasvir is an HCV NS5A inhibitor; peginterferon alfa-2a is a long-acting interferon stimulating antiviral immune responses; and ribavirin is a nucleoside analog with broad-spectrum antiviral activity. This combination acts via multiple mechanisms to inhibit viral replication and enhance immune-mediated clearance of HCV. Peginterferon and ribavirin were previously standard HCV therapies and are sometimes added to direct-acting antiviral regimens, particularly in patients with more advanced disease or specific genotypes.